Michael D. Pak

Array ( [id] => 18369127 [patent_doc_number] => 11649281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Antibody against human prostaglandin E2 receptor EP4 [patent_app_type] => utility [patent_app_number] => 16/555524 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 19357 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17113192 [patent_doc_number] => 20210293789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => RP182 COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/263409 [patent_app_country] => US [patent_app_date] => 2019-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17263409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050676 [patent_doc_number] => 20210260110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => NOVEL METHODS FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS [patent_app_type] => utility [patent_app_number] => 17/269659 [patent_app_country] => US [patent_app_date] => 2019-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454457 [patent_doc_number] => 20200040053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => Ligands Modified by Circular Permutation as Agonists and Antagonists [patent_app_type] => utility [patent_app_number] => 16/519231 [patent_app_country] => US [patent_app_date] => 2019-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175227 [patent_doc_number] => 20190358205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME [patent_app_type] => utility [patent_app_number] => 16/516566 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19013220 [patent_doc_number] => 11920138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Fusion proteins and methods thereof [patent_app_type] => utility [patent_app_number] => 16/507977 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 116 [patent_no_of_words] => 60369 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15996265 [patent_doc_number] => 20200174003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => FUSION PROTEINS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/508021 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267489 [patent_doc_number] => 20190382478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Nucleolin Antibodies [patent_app_type] => utility [patent_app_number] => 16/454966 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16454966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254225 [patent_doc_number] => 20190375846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 16/424676 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868707 [patent_doc_number] => 20190284595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => NOVEL POLYPEPTIDE AND METHOD OF PRODUCING IMP USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/425897 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545345 [patent_doc_number] => 11718685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Compositions and methods for targeting stromal cells for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/417125 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 36060 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178925 [patent_doc_number] => 20190360054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => METHOD FOR DIAGNOSIS OF METASTATIC CANCER OR TAXANE-BASED DRUG-RESISTANT CANCER BY USING LMCD1 PROTEIN AND GENE CODING THEREFOR [patent_app_type] => utility [patent_app_number] => 16/413014 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688773 [patent_doc_number] => 20210071249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => DIAGNOSTIC METHOD AND THERAPY [patent_app_type] => utility [patent_app_number] => 17/051930 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815424 [patent_doc_number] => 11421023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Anti-GP73 monoclonal antibodies and methods of obtaining the same [patent_app_type] => utility [patent_app_number] => 16/387282 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 60624 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 292 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038703 [patent_doc_number] => 20190330356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/382402 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14932951 [patent_doc_number] => 20190302113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS [patent_app_type] => utility [patent_app_number] => 16/375283 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14833411 [patent_doc_number] => 20190275106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => Anti-Angiogenic Gene Therapy Kit [patent_app_type] => utility [patent_app_number] => 16/364284 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929963 [patent_doc_number] => 20190300619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => GITR AGONISTS, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/358522 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14716183 [patent_doc_number] => 20190249155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES [patent_app_type] => utility [patent_app_number] => 16/355339 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16355339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582844 [patent_doc_number] => 20210017246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => IL-13 RECEPTOR ALPHA 2 TARGETED, ZETAKINE DIRECTED T CELL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/979475 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979475 [rel_patent_id] =>[rel_patent_doc_number] =>)